Back to top
more

Sarepta Therapeutics (SRPT)

(Real Time Quote from BATS)

$151.32 USD

151.32
83,301

-1.35 (-0.88%)

Updated Jul 16, 2024 10:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for SRPT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

8 items in cart

View Cart/Checkout

Sarepta Therapeutics, Inc. [SRPT]

Reports for Purchase

Showing records 341 - 360 ( 667 total )

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 341

05/22/2018

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 342

05/14/2018

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 343

05/07/2018

Company Report

Pages: 9

Myonexus and Limb Girdle Muscular Dystrophy; Modest Upward Revision to Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 344

05/04/2018

Company Report

Pages: 9

EMA Headwinds Remain, But Myonexus Partnership and Near-Term POC Shifts Focus Back to Pipeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 345

04/23/2018

Company Report

Pages: 8

Quantifying Downside Risk if the EMA Takes a Hardline

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 346

04/10/2018

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 347

03/15/2018

Company Report

Pages: 7

Potentially Solidifying Lead in Developing a Gene Therapy for DMD

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 348

03/12/2018

Company Report

Pages: 6

Exondys 51 Was Not a Onetime Hail Mary; Increasing 12-Month Target to $92

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 349

03/09/2018

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 350

03/02/2018

Company Report

Pages: 8

FDA Meeting Minutes Likely to Pave a Path for an NDA Submission for Golodirsen

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 351

02/12/2018

Company Report

Pages: 9

Hey, Sarepta! Next Time, Please Stay Ahead of the News!

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 352

02/08/2018

Company Report

Pages: 8

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 353

02/07/2018

Company Report

Pages: 8

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 354

02/06/2018

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 355

01/25/2018

Company Report

Pages: 9

More Kerfuffle With Peer Solid BioSciences IPO Pricing; and Partner Summit Provides a Mixed Data From PhaseOut DMD

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 356

01/09/2018

Company Report

Pages: 4

FY18 Guidance Inline-and Priced in; Pipeline Progress For the Upside.

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 10.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 357

01/05/2018

Company Report

Pages: 7

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 358

01/03/2018

Company Report

Pages: 8

Regulatory and Pipeline Progress Remain Key Drivers for the Stock; Revenue Guidance More of a Short-Term Trading Event.

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHATTOPADHYAY D

Price: 25.00

Research Provided by a Third Party

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 359

12/15/2017

Company Report

Pages: 8

Price: 24.95

Company: Sarepta Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 360

12/01/2017

Company Report

Pages: 31

Cementing Leadership in DMD; Making JW Look Prophetic, Hedgies Not So Much; Initiating With Buy and $75 Target

Provider: H.C. Wainwright & Co., Inc.

Price: 75.00

Research Provided by a Third Party